New Injectables For Knee OA Fuel US Joint Fluid Market
Executive Summary
Although several factors have recently slowed growth in the US market for joint fluid replacement, it remains large and vastly underpenetrated with an estimated 15.8 million knee osteoarthritis patients who are hoping to delay the need for a total knee arthroplasty. With a growing number of products in the pipeline and increasing adoption of new single-injection products, the US joint fluid market is projected to increase from approximately $924.4 million in 2015 to more than $1.07 billion by 2019, a CAGR of 4%.
You may also be interested in...
Knee OA: Growing Demand For Nonsurgical Options
The knee replacement market is posting flat growth across the board as more patients seek nonsurgical options to manage their pain. Although such treatments typically last only a few months, many patients willingly accept the durability tradeoff to avoid the cost and downtime associated with surgery.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.